Pharma channel feed – Endpoints News

Pharma channel feed

FDA rolls out an early and historic OK for Spark's pioneering gene therapy -- now let's talk price

8 years ago

Array joins Pfizer on anti-cancer combos, the latest in a string of binimetinib combinations

8 years ago

Stepping up behind Sanofi, Genentech rolls the DiCE on a new small molecule discovery pact

8 years ago

Aerie bags an early OK for its self-described blockbuster glaucoma drug Rhopressa, recruiting 100 reps

8 years ago

On a new deal spree, Regeneron buys into ISA in pursuit of a checkpoint combo

8 years ago

Severe job cuts at Teva incite massive worker strikes, shutting Israel down

8 years ago

What’s the big hurry, Novartis? Pharma giant scores a PRV shortcut for $130M

8 years ago

Boehringer antes up on a €627.5M deal for rights to Autifony’s schizophrenia drugs

8 years ago

Four months after patient death, FDA's hold lifted on Alnylam's fitusiran

8 years ago

Amicus CEO lobbied FDA to reverse FDA’s rejection of migalastat, claiming a delay of up to 7 years

8 years ago

Galapagos snags co-promotion rights on filgotinib — just before Gilead’s lock-up pact expires

8 years ago

Bristol-Myers teams up with Opdivo maker Ono Pharmaceutical on new I/O programs

8 years ago

The top 10 prospective blockbuster drug launches slated for 2018 — Evaluate

8 years ago

Teva axing 14,000 workers, putting R&D and manufacturing facilities on the block in massive restructuring

8 years ago

Teva sharpens ax, preps brutal cuts in R&D and across the group in face of crushing debt

8 years ago

When can FDA 'refuse to file' NDAs and BLAs? New draft guidance explains

8 years ago

Allergan buys an ailing Repros, bagging a women’s health drug for the pipeline

8 years ago

In latest blow to Eli Lilly, Sanofi wins FDA OK for Humalog me-too

8 years ago

Activists threaten to push for a sale of Alexion if execs can't jack up stock price

8 years ago

Taking on gamma delta T cells, bluebird pays $16M for TC BioPharm's tumor invading tech platform

8 years ago

Alexion lines up $40M upfront deal with Halozyme to develop a better, easier next-gen followup to Soliris

8 years ago

Juno inks deals with Eli Lilly, the Hutch as it looks to leapfrog leaders on BCMA

8 years ago

Cancer R&D tips the scales at the FDA as active INDs climb to record high

8 years ago

Clinical trial transparency improves at (some) biopharmas as J&J, Sanofi lead a pack trailed by Valeant and Allergan

8 years ago

First page Previous page 307 308 309310311 312 313 Next page Last page